Episode
Retatrutide: The Triple-Hormone Weight Breakthrough | Health and Fitness News
- Published
- Jul 24, 2026
- Duration seconds
- 121
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/e2621ad3b7a0f446
Actions
POST https://stenobird.com/v1/public/podcasts/health-news-today-2-min-news-the-daily-news-now-7685759/episodes/retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759/retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Eli Lilly’s experimental drug retatrutide is blowing the weight loss and diabetes world away—showing up to 23% body weight loss and stellar blood sugar control in phase three trials. Unlike Ozempic or Mounjaro, it hits three hormone receptors (GLP-1, GIP, glucagon) for a triple-threat approach, delivered weekly via injection. It’s already impressing in trials for both type two diabetes and severe obesity with heart disease, even outperforming expectations in the diabetes group. But don’t ignore the downsides: diarrhea, nausea, and constipation plagued many, with over 10% discontinuing treatment. Still, with FDA approval potentially on the horizon by early 2027, retatrutide could redefine how we tackle obesity and metabolic disease. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/e2621ad3b7a0f446